Recro Pharma Inc (REPH) Major Shareholder Sells $126,086.84 in Stock
Recro Pharma Inc (NASDAQ:REPH) major shareholder Scp Vitalife Partners Ii Lp sold 13,189 shares of the firm’s stock in a transaction dated Wednesday, December 27th. The shares were sold at an average price of $9.56, for a total transaction of $126,086.84. Following the sale, the insider now owns 2,243,064 shares of the company’s stock, valued at $21,443,691.84. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.
Shares of Recro Pharma Inc (NASDAQ:REPH) opened at $9.25 on Friday. The firm has a market cap of $176.90, a PE ratio of -4.22 and a beta of -0.50. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.35 and a current ratio of 1.59. Recro Pharma Inc has a 12 month low of $5.81 and a 12 month high of $10.59.
A number of analysts have weighed in on REPH shares. Zacks Investment Research lowered shares of Recro Pharma from a “hold” rating to a “sell” rating in a research note on Wednesday, October 11th. Piper Jaffray Companies restated a “buy” rating and set a $11.00 price objective on shares of Recro Pharma in a research note on Friday, October 27th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Recro Pharma has an average rating of “Buy” and an average target price of $11.65.
A number of large investors have recently added to or reduced their stakes in REPH. OxFORD Asset Management LLP boosted its holdings in shares of Recro Pharma by 364.3% during the 2nd quarter. OxFORD Asset Management LLP now owns 203,430 shares of the specialty pharmaceutical company’s stock valued at $1,430,000 after acquiring an additional 159,619 shares during the last quarter. State Street Corp purchased a new stake in shares of Recro Pharma during the 2nd quarter valued at about $1,047,000. Northern Trust Corp boosted its holdings in shares of Recro Pharma by 428.5% during the 2nd quarter. Northern Trust Corp now owns 178,437 shares of the specialty pharmaceutical company’s stock valued at $1,254,000 after acquiring an additional 144,676 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Recro Pharma by 787.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 129,560 shares of the specialty pharmaceutical company’s stock valued at $911,000 after acquiring an additional 114,960 shares during the last quarter. Finally, JT Stratford LLC purchased a new stake in shares of Recro Pharma during the 2nd quarter valued at about $704,000. Institutional investors and hedge funds own 61.55% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Recro Pharma Inc (REPH) Major Shareholder Sells $126,086.84 in Stock” was originally published by Watch List News and is the property of of Watch List News. If you are viewing this news story on another site, it was illegally stolen and republished in violation of United States & international trademark and copyright laws. The original version of this news story can be viewed at https://www.watchlistnews.com/recro-pharma-inc-reph-major-shareholder-sells-126086-84-in-stock/1789799.html.
Recro Pharma Company Profile
Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.
Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with Analyst Ratings Network's FREE daily email newsletter.